Skip Navigation

Cardiovascular Research 2001 51(3):372-390; doi:10.1016/S0008-6363(01)00328-5
© 2001 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bankir, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bankir, L.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2000, European Society of Cardiology

Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects

Lise Bankir*

INSERM Unité 367, 17 Rue du Fer à Moulin, 75005 Paris, France

bankir{at}ifm.inserm.fr

* Tel.: +33-1-45-8761-21; fax: +33-1-45-35-6629 or +33-1-47-46-9956

(1) Vasopressin (VP), or antidiuretic hormone, is secreted in response to either increases in plasma osmolality (very sensitive stimulus) or to decreases in plasma volume (less sensitive stimulus). Its normal plasma level is very low (about 1 pg/ml, i.e. 10–12 M), close to the detection limit of present immunoassays, and distinct antidiuretic effects are observed after infusion of small undetectable amounts of VP. (2) This antidiuretic action results from three main effects of VP on principal cells of the collecting duct (CD) mediated by occupancy of peritubular V2 receptors. (i) Increase in water permeability along the entire CD (via AQP2). (ii) Increase in urea permeability in only the terminal inner medullary CD (via UT-A1). (iii) Stimulation of sodium reabsorption, mainly in the cortical and outer medullary CD (via ENaC). VP also acts on medullary vasculature (V1a receptors) to reduce blood flow to inner medulla without affecting blood flow to outer medulla. Besides these actions, all concurring to increase urine osmolality in different and additive ways, other VP effects, probably exerted through V1a receptors located on luminal membrane, tend to limit the antidiuretic effects of the hormone. They induce the formation of prostaglandins which reduce V2-dependent cAMP accumulation in these cells and thus partially inhibit all three V2 effects. (3) Because urine is first diluted along the nephron before being concentrated in the medulla, VP is required, not only for urine concentration, but first for re-equilibration of tubular fluid osmolality with plasma osmolality, a step taking place in the renal cortex, and achieved through the reabsorption of large quantities of water (more than what is subsequently reabsorbed in the medulla to concentrate urine). Accordingly, VP effects on urine flow-rate are not linear. Small changes in plasma VP in the low range of urine osmolality will induce wide changes in urinary flow-rate, whereas in the upper range of urine osmolality larger changes in plasma VP induce much more limited further reduction in urine flow-rate. (4) Most likely, the different effects of VP require different levels of VP concentration to occur and are thus recruited successively with progressive rise in VP secretion.

KEYWORDS VP, Vasopressin; ADH, Antidiuretic hormone (=vasopressin); dDAVP, deamino-8D-arginine vasopressin; DI, Diabetes insipidus; V1aR, V1bR, V2R, VP receptors V1a, V1B and V2; PVP, Plasma vasopressin concentration; Posm, Plasma osmolality; Uosm, Urine osmolality; CH2O, Solute-free water clearance; TcH2O, Solute-free water reabsorption; GFR, Glomerular filtration rate; TAL, Thick ascending limb of Henle's loop; DCT, Distal convoluted tubule; CNT, Connecting tubule; CD, Collecting duct; CCD, Cortical collecting duct; IMCD, Inner medullary collecting duct; OM, Outer medulla; IM, Inner medulla; AQP2, Aquaporin 2; ENaC, Epithelial sodium channel; UT-A1, Urea transporter A1


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
V. Bugaj, O. Pochynyuk, and J. D. Stockand
Activation of the epithelial Na+ channel in the collecting duct by vasopressin contributes to water reabsorption
Am J Physiol Renal Physiol, November 1, 2009; 297(5): F1411 - F1418.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Biol.Home page
N. Konno, S. Hyodo, Y. Yamaguchi, H. Kaiya, M. Miyazato, K. Matsuda, and M. Uchiyama
African lungfish, Protopterus annectens, possess an arginine vasotocin receptor homologous to the tetrapod V2-type receptor
J. Exp. Biol., July 15, 2009; 212(14): 2183 - 2193.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
V. E. Torres, L. Bankir, and J. J. Grantham
A Case for Water in the Treatment of Polycystic Kidney Disease
Clin. J. Am. Soc. Nephrol., June 1, 2009; 4(6): 1140 - 1150.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
G. Alonso, E. Galibert, V. Boulay, A. Guillou, A. Jean, V. Compan, and G. Guillon
Sustained Elevated Levels of Circulating Vasopressin Selectively Stimulate the Proliferation of Kidney Tubular Cells via the Activation of V2 Receptors
Endocrinology, January 1, 2009; 150(1): 239 - 250.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
Y. Izumi, Y. Nakayama, H. Memetimin, T. Inoue, Y. Kohda, H. Nonoguchi, and K. Tomita
Regulation of V2R transcription by hypertonicity and V1aR-V2R signal interaction
Am J Physiol Renal Physiol, October 1, 2008; 295(4): F1170 - F1176.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
J. Perucca, D. G. Bichet, P. Bardoux, N. Bouby, and L. Bankir
Sodium Excretion in Response to Vasopressin and Selective Vasopressin Receptor Antagonists
J. Am. Soc. Nephrol., September 1, 2008; 19(9): 1721 - 1731.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
B. Bishara, H. Shiekh, T. Karram, I. Rubinstein, Z. S. Azzam, N. Abu-Saleh, S. Nitecki, J. Winaver, A. Hoffman, and Z. A. Abassi
Effects of Novel Vasopressin Receptor Antagonists on Renal Function and Cardiac Hypertrophy in Rats with Experimental Congestive Heart Failure
J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 414 - 422.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. J. Finley IV, M. A. Konstam, and J. E. Udelson
Arginine Vasopressin Antagonists for the Treatment of Heart Failure and Hyponatremia
Circulation, July 22, 2008; 118(4): 410 - 421.
[Full Text] [PDF]


Home page
CJASNHome page
V. E. Torres
Role of Vasopressin Antagonists
Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1212 - 1218.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
E. Stafflinger, K. K. Hansen, F. Hauser, M. Schneider, G. Cazzamali, M. Williamson, and C. J. P. Grimmelikhuijzen
Cloning and identification of an oxytocin/vasopressin-like receptor and its ligand from insects
PNAS, March 4, 2008; 105(9): 3262 - 3267.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
K. Mutig, A. Paliege, T. Kahl, T. Jons, W. Muller-Esterl, and S. Bachmann
Vasopressin V2 receptor expression along rat, mouse, and human renal epithelia with focus on TAL
Am J Physiol Renal Physiol, October 1, 2007; 293(4): F1166 - F1177.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
A. K. Ahrabi, S. Terryn, G. Valenti, N. Caron, C. Serradeil-Le Gal, D. Raufaste, S. Nielsen, S. Horie, J.-M. Verbavatz, and O. Devuyst
PKD1 Haploinsufficiency Causes a Syndrome of Inappropriate Antidiuresis in Mice
J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1740 - 1753.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
Y. Izumi, Y. Nakayama, T. Mori, H. Miyazaki, H. Inoue, Y. Kohda, T. Inoue, H. Nonoguchi, and K. Tomita
Downregulation of vasopressin V2 receptor promoter activity via V1a receptor pathway
Am J Physiol Renal Physiol, May 1, 2007; 292(5): F1418 - F1426.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
J. Perucca, N. Bouby, P. Valeix, and L. Bankir
Sex difference in urine concentration across differing ages, sodium intake, and level of kidney disease
Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2007; 292(2): R700 - R705.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
M. Carmosino, H. L. Brooks, Q. Cai, L. S. Davis, S. Opalenik, C. Hao, and M. D. Breyer
Axial heterogeneity of vasopressin-receptor subtypes along the human and mouse collecting duct
Am J Physiol Renal Physiol, January 1, 2007; 292(1): F351 - F360.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
W. A. Windt, A. Tahara, A. C. Kluppel, D. de Zeeuw, R. H Henning, and R. P. van Dokkum
Early, but not late therapy with a vasopressin V1a-antagonist ameliorates the development of renal damage after 5/6 nephrectomy
Journal of Renin-Angiotensin-Aldosterone System, December 1, 2006; 7(4): 217 - 224.
[Abstract] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
D. Zhao, L. Bankir, L. Qian, D. Yang, and B. Yang
Urea and urine concentrating ability in mice lacking AQP1 and AQP3
Am J Physiol Renal Physiol, August 1, 2006; 291(2): F429 - F438.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
S. Petrovic, H. Amlal, X. Sun, F. Karet, S. Barone, and M. Soleimani
Vasopressin induces expression of the Cl-/HCO3- exchanger SLC26A7 in kidney medullary collecting ducts of Brattleboro rats
Am J Physiol Renal Physiol, May 1, 2006; 290(5): F1194 - F1201.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
L. Bankir, S. Fernandes, P. Bardoux, N. Bouby, and D. G. Bichet
Vasopressin-V2 Receptor Stimulation Reduces Sodium Excretion in Healthy Humans
J. Am. Soc. Nephrol., July 1, 2005; 16(7): 1920 - 1928.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
X. Wang, V. Gattone II, P. C. Harris, and V. E. Torres
Effectiveness of Vasopressin V2 Receptor Antagonists OPC-31260 and OPC-41061 on Polycystic Kidney Disease Development in the PCK Rat
J. Am. Soc. Nephrol., April 1, 2005; 16(4): 846 - 851.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
M. R. McReynolds, K. M. Taylor-Garcia, K. A. Greer, J. B. Hoying, and H. L. Brooks
Renal medullary gene expression in aquaporin-1 null mice
Am J Physiol Renal Physiol, February 1, 2005; 288(2): F315 - F321.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
P. J. Kemp and K.-J. Kim
Spectrum of ion channels in alveolar epithelial cells: implications for alveolar fluid balance
Am J Physiol Lung Cell Mol Physiol, September 1, 2004; 287(3): L460 - L464.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
P. Bardoux, P. Bruneval, D. Heudes, N. Bouby, and L. Bankir
Diabetes-induced albuminuria: role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats
Nephrol. Dial. Transplant., September 1, 2003; 18(9): 1755 - 1763.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
R. Schmitt, E. Klussmann, T. Kahl, D. H. Ellison, and S. Bachmann
Renal expression of sodium transporters and aquaporin-2 in hypothyroid rats
Am J Physiol Renal Physiol, May 1, 2003; 284(5): F1097 - F1104.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
R. K. Handa, J. W. Strandhoy, C. E. Giammattei, and S. E. Handa
Platelet-activating factor and solute transport processes in the kidney
Am J Physiol Renal Physiol, February 1, 2003; 284(2): F274 - F281.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
J. A. Schafer
Abnormal regulation of ENaC: syndromes of salt retention and salt wasting by the collecting duct
Am J Physiol Renal Physiol, August 1, 2002; 283(2): F221 - F235.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.